U.S., May 15 -- ClinicalTrials.gov registry received information related to the study (NCT07587840) titled 'CD19/CD22 CAR-T as First-line Consolidation in Follicular Lymphoma' on May 04.
Brief Summary: The purpose of this study is to determine the efficacy and safety of CD19/CD22 Chimeric Antigen Receptor (CAR) T-Cell immunotherapy as first-line consolidation therapy in patients with follicular lymphoma.
Study Start Date: Jan. 01
Study Type: INTERVENTIONAL
Condition:
Lymphoma
Intervention:
BIOLOGICAL: CD22/CD19 CAR-T cell immunotherapy
Autologous T cells were collected and genetically modified to express chimeric antigen receptors targeting CD19 and CD22. Following lymphodepleting chemotherapy, patients received a single intravenous...